Published in Int J Gynecol Cancer on July 01, 2016
Efforts towards erasing borders in gynecologic cancer? Gynecol Oncol Rep (2017) 0.75
Strengthening care and research for women's cancers in Sub-Saharan Africa. Gynecol Oncol Rep (2017) 0.75
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002) 6.51
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol (2010) 5.65
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy? J Clin Oncol (2007) 5.14
Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol (2003) 4.77
How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol (2002) 4.68
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
Ovarian cancer. Lancet (2009) 3.95
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (2004) 3.57
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis (2005) 3.50
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Vaginal cuff recurrence of endometrial cancer treated by laparoscopic-assisted vaginal hysterectomy. Gynecol Oncol (2003) 3.39
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. Lancet Oncol (2013) 3.12
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol (2011) 2.76
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Focus on epithelial ovarian cancer. Cancer Cell (2004) 2.47
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol (2009) 2.45
Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis (2005) 2.42
Chapter 8: Screening for cervical cancer in developing countries. Vaccine (2006) 2.35
Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys (2007) 2.34
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
Distinguishing the temporal association between women's intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. Am J Epidemiol (2006) 2.28
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res (2005) 2.24
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol (2008) 2.14
Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst (2003) 2.11
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol (2006) 2.10
Pathophysiology and management of radiation-induced xerostomia. J Support Oncol (2005) 2.09
Incidence of venous thromboembolism after minimally invasive surgery in patients with newly diagnosed endometrial cancer. Obstet Gynecol (2012) 2.09
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst (2008) 2.08
Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol (2006) 2.07
The role of adjuvant radiation in endometrial cancer. Oncology (Williston Park) (2009) 2.07
Treatment of cancer in sub-Saharan Africa. Lancet Oncol (2013) 2.07
Cytoreductive surgery for advanced ovarian cancer: quo vadis? Oncology (Williston Park) (2011) 2.05
The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecol Oncol (2011) 2.04
Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol (2006) 2.04
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer (2006) 2.03
Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer (2011) 2.02
Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst (2006) 2.01
The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer (2009) 1.97
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol (2002) 1.93
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol (2013) 1.92
Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets (2010) 1.91
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol (2012) 1.90
Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol (2008) 1.89
Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol (2010) 1.89
Facilitation of radiotherapeutic error by computerized record and verify systems. Int J Radiat Oncol Biol Phys (2003) 1.88
HPV communication: review of existing research and recommendations for patient education. CA Cancer J Clin (2004) 1.88
Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer (2010) 1.88
The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer (2006) 1.84
Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol (2007) 1.84
Radiation-induced lung injury. Semin Radiat Oncol (2003) 1.82
Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer (2006) 1.82
Laparoscopic management of early uterine cancer: 10-year experience in Asan Medical Center. Gynecol Oncol (2007) 1.81
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol (2007) 1.80
Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol (2007) 1.79
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys (2005) 1.77
Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol (2010) 1.77
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol (2003) 1.74
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol (2006) 1.73
Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys (2010) 1.73
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol (2011) 1.73
Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer (2013) 1.71
Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. Cancer (2006) 1.71
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther (2010) 1.71
The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol (2010) 1.70
Radical hysterectomy in obese and morbidly obese women with cervical cancer. Obstet Gynecol (2008) 1.70
Selecting high priority quality measures for breast cancer quality improvement. Med Care (2008) 1.70
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. Obstet Gynecol (2004) 1.69
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2007) 1.69
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res (2007) 1.68
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res (2007) 1.66
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol (2006) 1.64
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol (2005) 1.62
Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res (2003) 1.62
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61
Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol (2006) 1.61
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol (2012) 1.61
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer (2010) 1.61
Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. Int J Radiat Oncol Biol Phys (2007) 1.61
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol (2004) 1.60